Harrow, Inc. Finite-Lived Intangible Asset, Expected Amortization, Year One
Harrow, Inc. (HROW) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $20.24 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2026-08-10
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $20.24M.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $19.37M.
- 2025-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $16.71M.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $16.90M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One |
|---|---|
| 2026-06-30 | $20.24M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $19.37M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $16.71M 10-K · filed 2026-03-02 |
| 2025-09-30 | $16.90M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $16.90M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $16.90M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $16.90M 10-K · filed 2025-03-27 |
| 2024-09-30 | $16.63M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $13.66M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $13.66M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $13.66M 10-K · filed 2024-03-19 |
| 2023-09-30 | $13.79M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $11.79M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $11.67M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $2.52B 10-K · filed 2023-03-23 |
| 2022-09-30 | $2.09M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $1.59M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $1.59M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $1.60M 10-K · filed 2022-03-10 |
| 2021-09-30 | $188.00K 10-Q · filed 2021-11-09 |
| 2021-06-30 | $188.00K 10-Q · filed 2021-08-10 |
| 2021-03-31 | $188.00K 10-Q · filed 2021-05-11 |
| 2020-12-31 | $187.00K 10-K · filed 2021-03-08 |
| 2020-09-30 | $173.00K 10-Q · filed 2020-11-09 |
| 2019-12-31 | $187.00K 10-K · filed 2020-03-13 |
| 2018-12-31 | $242.00K 10-K · filed 2019-03-12 |
| 2018-06-30 | $231.00K 10-Q · filed 2018-08-06 |
| 2018-03-31 | $228.00K 10-Q · filed 2018-05-15 |
| 2017-12-31 | $228.00K 10-K · filed 2018-03-08 |
| 2017-03-31 | $271.00K 10-Q · filed 2017-05-10 |
| 2016-12-31 | $359.00K 10-K · filed 2017-03-21 |
| 2016-09-30 | $90.00K 10-Q · filed 2016-11-14 |
| 2016-06-30 | $185.00K 10-Q · filed 2016-08-15 |
| 2016-03-31 | $276.00K 10-Q · filed 2016-05-12 |
| 2015-12-31 | $365.00K 10-K · filed 2016-03-23 |
| 2015-09-30 | $90.00K 10-Q · filed 2015-11-12 |
| 2015-06-30 | $174.00K 10-Q · filed 2015-08-12 |
| 2015-03-31 | $247.00K 10-Q · filed 2015-05-13 |
| 2014-12-31 | $67.09K 10-K · filed 2015-03-12 |
| 2014-09-30 | $16.85K 10-Q · filed 2014-11-12 |
| 2014-06-30 | $23.60K 10-Q · filed 2014-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |